Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology

Cellular and molecular mechanisms of statins: an update on pleiotropic effects

(2015) Mamoru Satoh et al.   CLINICAL SCIENCE

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9

(2015) Michael M. Page et al.   CLINICAL SCIENCE

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

(2015) Rocco Romagnuolo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2015) Brian R. Ott et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorting an LDL receptor with bound PCSK9 to intracellular degradation

(2014) Trond P. Leren   ATHEROSCLEROSIS

Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) gain-of-function mutation

(2014) Hiroshi Mabuchi et al.   ATHEROSCLEROSIS

Latest developments in the treatment of lipoprotein (a)

(2014) Sven Bos et al.   CURRENT OPINION IN LIPIDOLOGY

AMG-145

(2014) E.A. Stein et al.   DRUGS OF THE FUTURE

Lipoprotein(a)

(2014) Marlys L. Koschinsky et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?

(2014) Helen I Keen et al.   Expert Opinion On Drug Safety

Lipoprotein(a) as a therapeutic target in cardiovascular disease

(2014) Marlys Koschinsky et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipid lowering with PCSK9 inhibitors

(2014) Razvan T. Dadu et al.   Nature Reviews Cardiology

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Resistance and intolerance to statins

(2014) Ž. Reiner   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease

(2013) Brian A Ference et al.   Current Atherosclerosis Reports

Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

(2013) A Caruz et al.   GENES AND IMMUNITY

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

(2013) Gerald F. Watts et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Statins in the primary prevention of cardiovascular disease

(2013) Željko Reiner   Nature Reviews Cardiology

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

(2013) Frederick Raal et al.   Journal of the American Heart Association

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

(2012) Kai Kysenius et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

(2012) Clapton S. Dias et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

(2012) Mary P. McGowan et al.   PLoS One

Statin Therapy and the Risk of Intracerebral Hemorrhage

(2012) James S. McKinney et al.   STROKE

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis

(2011) Meng Lee et al.   ATHEROSCLEROSIS

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

(2011) M. John Chapman et al.   EUROPEAN HEART JOURNAL

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

(2011) Estelle Rousselet et al.   JOURNAL OF LIPID RESEARCH

Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey

(2010) Željko Reiner et al.   ATHEROSCLEROSIS

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA